Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Double Blind, Placebo Controlled Phase 3 Study of the Efficacy of an Investigational Vero Cell-Derived Influenza Vaccine to Prevent Culture Confirmed Influenza Infection.

Next Previous
X
Search
Trial Profile

Double Blind, Placebo Controlled Phase 3 Study of the Efficacy of an Investigational Vero Cell-Derived Influenza Vaccine to Prevent Culture Confirmed Influenza Infection.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 31 May 2018

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Influenza virus vaccine (Primary)
  • Indications Influenza A virus H1N1 subtype; Influenza A virus H3N2 subtype; Influenza B virus infections
  • Focus Registrational; Therapeutic Use
  • Sponsors Baxter Healthcare Corporation

    • Most Recent Events

    • 16 Feb 2011 Results published in the Lancet, according to a Baxter Healthcare media release.
    • 12 Mar 2010 Results have been presented at the International Congress on Infectious Disease (ICID 2010), according to a Baxter International media release.
    • 29 Oct 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top